This phase III trial is comparing the safety and effectiveness of a type of targeted therapy, with a type of chemotherapy, for the treatment of advanced non-squamous non-small cell lung cancer that has progressed, despite previously being treated.
This trial is treating patients with non-small cell lung cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You are able to swallow medication by mouth.
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 3, Randomized, Open-label, Multicenter Study of the Efficacy and Safety of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Harboring a HER2 Exon 20 Mutation Who Progressed on or After Treatment With Platinum Based Chemotherapy
Jiangsu HengRui Medicine Co., Ltd.
Eligible patients will be randomised to receive either a 400mg Pyrotinib maleate tablet once daily on a continuous dosing schedule over a 21-day cycle, OR a 75mg/m2 docetaxel injection once every three-weeks.
Recruiting Hospitals Read More